Valvular heart disease and cardiomyopathy: reappraisal of their interplay

: Marsan Nina Ajmone, Graziani Francesca, Meucci Maria Chiara, Wu Hoi W., Lillo Rosa, Bax Jeroen J., Burzotta Francesco, Massetti Massimo, Jukema J. Wouter, Crea Filippo

Publisher: NATURE PORTFOLIO

: 2023

: Nature Reviews Cardiology

: NATURE REVIEWS CARDIOLOGY

: NAT REV CARDIOL

: 14

: 1759-5002

: 1759-5010

DOI: https://doi.org/10.1038/s41569-023-00911-0

: https://doi.org/10.1038/s41569-023-00911-0

Cardiomyopathies and valvular heart diseases are typically considered distinct diagnostic categories with dedicated guidelines for their management. However, the interplay between these conditions is increasingly being recognized and they frequently coexist, as in the paradigmatic examples of dilated cardiomyopathy and hypertrophic cardiomyopathy, which are often complicated by the occurrence of mitral regurgitation. Moreover, cardiomyopathies and valvular heart diseases can have a shared aetiology because several genetic or acquired diseases can affect both the cardiac valves and the myocardium. In addition, the association between cardiomyopathies and valvular heart diseases has important prognostic and therapeutic implications. Therefore, a better understanding of their shared pathophysiological mechanisms, as well as of the prevalence and predisposing factors to their association, might lead to a different approach in the risk stratification and management of these diseases. In this Review, we discuss the different scenarios in which valvular heart diseases and cardiomyopathies coexist, highlighting the need for an improved classification and clustering of these diseases with potential repercussions in the clinical management and, particularly, personalized therapeutic approaches.In this Review, Marsan et al. discuss the different clinical scenarios in which valvular heart diseases and cardiomyopathies coexist, either as the cause of one another or because of a common aetiology, to highlight the need for an improved classification of these diseases with potential repercussions in clinical management and personalized treatment.